Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

PBLS

Parabilis Medicines Inc

Jun 11 • 04:00PM ET

30.31

-1.29 -4.08 %

Healthcare • Biotechnology • USA • Micro • NASD

Jun 11, 4:10 PMParabilis closes upsized Nasdaq IPO and $75M Regeneron private placement, raising $845.5M and converting preferred and $50M SAFE

Held by: ONEQ

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	118.15M	Perf Week	-
Market Cap	99.11M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	-	Perf Month	-
Enterprise Value	637.76M	PEG	-	EPS next Q	-	Inst Own	-	Short Float	-	Perf Quarter	-
Income	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	-	Perf Half Y	-
Sales	-	P/B	-	EPS next Y	-	ROA	-	Short Interest	-	Perf YTD	-4.08%
Book/sh	-4.83	P/C	0.30	EPS next 5Y	-	ROE	-	52W High	34.01 -10.89%	Perf Year	-
Cash/sh	100.62	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	26.61 13.90%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	- -	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	6.11	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.12	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	-	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	6.12	EPS Q/Q	-	SMA20	-2.08%	Beta	-	Target Price	-
Payout	-	Debt/Eq	0.22	Sales Q/Q	-	SMA50	-2.08%	Rel Volume	0.29	Prev Close	31.60
Employees	-	LT Debt/Eq	0.15	Earnings	-	SMA200	-2.08%	Avg Volume	3.55M	Price	30.31
IPO	Jun 10, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	1,600,345	Change	-4.08%

Jun-11-26 04:05PM	Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Jun-09-26 08:22PM	Parabilis Medicines Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PBLS

Parabilis Medicines Inc

Upgrade your Finviz experience